Home > Research Institute > Available Trials > Phase 3 Study of MK-6482 with Lenvatinib for Metastatic Renal Cell Cancer Patients
Phase 3 Study of MK-6482 with Lenvatinib for Metastatic Renal Cell Cancer Patients
An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After 1 Prior Anti-PD-1/L1 Combination Regimen
Disease Types: Renal
Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville
An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After 1 Prior Anti-PD-1/L1 Combination Regimen
For more information:
https://clinicaltrials.gov/ct2/show/NCT04586231?term=MK-6482-011&draw=2&rank=1